Hopital Pellegrin
Bordeaux, 33000, France
NCT Number: NCT04371029
Most patients in intensive care units (ICUs) experience severe sleep disruption. Sleep disruption and sleep alteration may have an influence on the ability to breathe spontaneously. But, the cause of altered sleep remains unknown. Previous studies have shown that decreasing nocturnal respiratory muscle activity through mechanical ventilation might improve sleep quality. Nocturnal respiratory muscle activity may be one of the potential factor which contribute to alter sleep in the ICU. Therefore, the aim of this study is to analyse the presence of NIM activation during the night and it's consequence in an ICU population with the same pathology (COVID 19 ARDS).
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Bordeaux, 33000, France
Sleep alteration is a common problem among ventilated ICU patient. About one third of the patient have abnormal EEG pattern which cannot be scored by using the AASM standard criteria. Patients experience marked fragmentation, absence of deep sleep, and REM sleep is decreased, . It has been shown that sleep deprivation has a negative impact on respiratory muscle endurance. So a good sleep is essential when the respiratory system is being challenged, as in the ICU during the weaning period. Indeed, in the ICU, patients with altered sleep, had a markedly longer weaning duration than in patients with normal sleep, and are more likely to fail a spontaneous breathing trial. Many factors may influence the quality of sleep in the ICU (noise, medication, mechanical ventilation …) but few studies have focus on the cause of this altered sleep, and the cause of altered sleep remains unknown. Previous studies have shown that decreasing nocturnal respiratory muscle activity through mechanical ventilation might improve sleep quality. Mechanical ventilation can decrease the charge imposed on the respiratory pump, and allows muscle to rest. Indeed, when the charge is too high (for example after an ARDS during the weaning period), the diaphragm may be overloaded, and there could be a greater involvement of other inspiratory muscles in breathing. In other pathological condition, the neck inspiratory muscle activity is increased (e.g. COPD, amyotrophic lateral sclerosis), and sometimes this activity persist during sleep with marked degradation in sleep architecture. Nocturnal respiratory muscle activity may be one of the potential factor which contribute to alter sleep in the ICU. Ttherefore, the aim of tis study is to analyse the presence of NIM activation during the night and it's consequence in an ICU population with the same pathology (COVID 19 ARDS).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Polysomnography at 3 times, actimetry measure and Pittsburgh questionnaire
Time frame: At day 10 after inclusion
Comparison between patients with NIM activation during the night and patients without NIM activation during the night, in patients COVID 19 ARDS with altered spleep. A Polysomnography (PSG) will be performed the night before extubation.
Time frame: At day 28 after inclusion
Thanks to a PSG the night befor discharge, the seep architecture will be estimated.
Time frame: At day 18 after ICU discharge
Thanks to actimetry measure during hospitalization in the post ICU ward.
Time frame: 3 months after hospiotal discharge
Sleep quality will be evaluate by the Pittsburgh sleep quality index. The 7 components of the score add up for give an overall score ranging from 0 to 21 points, 0 meaning that there is no difficulty, and 21 indicating on the contrary major difficulties.
Time frame: 3 months after hospital discharge
Thanks to a PSG at 3 months, the seep architecture will be estimated.
Time frame: From inclusion to ICU discharge, up to 10 days after inclusion
all cost will be estimated during ICU hospitalization.
University Hospital, Bordeaux
Other
Acronym: COVISLEEP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04402879
ARDS, Acute Respiratory Distress Syndrome
Calgary, Alberta, Canada
View Trial DetailsNCT06038682
ARDS, Acute Lung Injury
Ostrava, Moravian-Silesian Region, Czechia
View Trial DetailsNCT04493242
ARDS, COVID-19
Sheffield, Alabama, United States
View Trial DetailsNCT05336656
ARDS, COVID-19
Wilkes-Barre, Pennsylvania, United States
View Trial Details